Acasti Pharma (CVE:ACST) Shares Up 1.8% – Should You Buy?

Shares of Acasti Pharma Inc. (CVE:ACST – Get Free Report) traded up 1.8% on Tuesday . The stock traded as high as C$0.58 and last traded at C$0.58. Approximately 2,450 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 6,576 shares. The stock had previously closed at C$0.57.

Acasti Pharma Stock Up 1.8%

The firm has a market capitalization of C$18.19 million, a P/E ratio of -1.21 and a beta of 1.22. The firm’s 50-day simple moving average is C$0.58 and its 200-day simple moving average is C$0.58.

About Acasti Pharma

(Get Free Report)

Acasti Pharma Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Read More

• Five stocks we like better than Acasti Pharma
• Apple and Broadcom Forge a Decade-Long Silicon Fortress
• SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
• The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
• Palantir’s CEO Just Called Out OpenAI and Anthropic